Showing results (21-30 of 84) with videos related to
Sort By:
Pageof 9
Journal of Managed Care & Specialty Pharmacy|June 2, 2024
US commercial health plan coverage dynamics in pulmonary arterial hypertension therapiesJulia A Rucker, Molly T Beinfeld, Daniel E Enright, et al.Pharmacoeconomics|May 27, 2014
Do changes in drug coverage policy point to an increased role for cost-effectiveness analysis in the USA?James D ChambersThe New England Journal of Medicine|November 2, 2012
Medicare's enduring struggle to define "reasonable and necessary" carePeter J Neumann, James D ChambersValue in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 23, 2016
Thirty Years of Media Coverage on High Drug Prices in the United States--A Never-Ending Story or a Time for Change?Christine Leopold, James D Chambers, Anita K WagnerJournal of Managed Care & Specialty Pharmacy|June 29, 2018
Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for HemophiliaTeja Thorat, Peter J Neumann, James D ChambersHealth Policy (Amsterdam, Netherlands)|December 16, 2014
Medicare's use of cost-effectiveness analysis for prevention (but not for treatment)James D Chambers, Michael J Cangelosi, Peter J NeumannHealth Affairs (Project Hope)|June 5, 2013
Medicare covers the majority of FDA-approved devices and Part B drugs, but restrictions and discrepancies remainJames D Chambers, Katherine E May, Peter J NeumannMedical Decision Making : an International Journal of the Society for Medical Decision Making|June 17, 2010
Does Medicare have an implicit cost-effectiveness threshold?James D Chambers, Peter J Neumann, Martin J BuxtonClinical Therapeutics|July 22, 2024
Balancing Evidence and Need: Variation in US Commercial Payer Coverage of EsketamineEkwu B Ochigbo, Molly T Beinfeld, James D ChambersThe American Journal of Managed Care|August 20, 2016
The impact of formulary drug exclusion policies on patients and healthcare costsJames D Chambers, Pallavi B Rane, Peter J NeumannPageof 9